Endocrine Abstracts (2009) 20 P594

Dose interval comparison of Lanreotide Autogel 120 mg in acromegalic patients previously treated with Octreotide LAR

Jochen Schopohl1, Klaus Badenhoop2, Felix Beuschlein1, Michael Droste3, Ursula Plöckinger4, Stephan Petersenn5 & Christian Strasburger6


1Medizinische Klinik Innenstadt, University Munich, Munich, Germany; 2Endokrinlogie, University Frankfurt, Frankfurt, Germany; 3Endokrinologie Praxis, Oldenburg, Germany; 4Campus Virchow, Charite Berlin, Berlin, Germany; 5Endokrinologie, Universitätsklinikum Essen, Essen, Germany; 6Campus Mitte, Charite Berlin, Berlin, Germany.


Acromegalic patients under treatment with Octreotide LAR (Oct), 10, 20 or 30 mg were switched to Lanreotide Autogel 120 mg (Lan) at different dose intervals: 56, 42 and 28 days respectively. Just before the fourth Lan injection, IGF-I values were measured and the dose interval for the final three injections adjusted accordingly: if IGF-I values were between 1 and 2 standard deviations (S.D.) above the age and sex related mean value, no change in dose-interval was made; if IGF-I was above 2 S.D., the dose interval was reduced (from 56 to 42 or 42 to 28 days); if the IGF-I value was below 1 S.D., the dose interval was increased (from 28 to 42 or 42 to 56 days).

The ITT population comprised 37 patients who were treated at least once; 33 were titrated and 18, 7 and 8 patients finished the study with 28, 42 and 56 day injection intervals respectively.

Median IGF-I, GH and quality of life (QUOL) values were similar at study start and end: IGF-I 89.6 and 87.9% of upper limit of normal range; GH 1.02 and 1.64 ng/ml; QUOL 66 and 66%.

Fifty-one percent of investigators preferred the Lan Injections and 26% Oct. Patients on the longer injection intervals seemed to prefer the Lan treatment more: 41, 54 and 71% of the patients in the 28, 42 and 56 day groups expressed a preference for treatment with Lan (Oct: 35, 9 and 29% respectively).

No treatment-related serious or unexpected adverse events occurred.

Conclusions: Lanreotide Autogel 120 mg injected at intervals of 28, 42 and 56 days provided equivalent control of IGF-I, GH and QUOL when compared to treatment with 30, 20 and 10 mg Octreotide LAR respectively. For patients requiring lower doses, a longer injection interval leads to a higher preference for the treatment.

Article tools

My recent searches

No recent searches.